Nurix Therapeutics, Inc

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL)

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton's tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST) on Monday, December 11, 2023.

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that clinical data will be presented for its two BTK degrader programs, NX-5948 and NX-2127, in two posters at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA. Nurix will also present a trials in progress poster for its NX-1607 program.

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. Screening and enrollment of new study participants has been paused.

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

AbCellera Biologics

Groupon

Renalytix AI plc

Smartsheet

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.

New Strong Buy Stocks for October 26th

Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.90 per share a year ago.

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.

Nurix (NRIX) to Report Q3 Earnings: What's in Store?

Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

From a technical perspective, Nurix Therapeutics, Inc. (NRIX) is looking like an interesting pick, as it just reached a key level of support. NRIX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors

Nurix Therapeutics, Inc. (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know

The consensus price target hints at a 215.3% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet

The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.

Nurix (NRIX) Stock Increases 9% in a Month: Here's Why

Nurix Therapeutics, Inc. (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?

The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 195.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.01 per share a year ago.

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates

Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin's lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Received $20 million licensing payment from Gilead for NX-0479, an oral IRAK4 degrader for the treatment of rheumatoid arthritis and inflammatory diseases Maintained strong financial position with cash and marketable securities of $308.6 million as of May 31, 2023 SAN FRANCISCO, July 13, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended May 31, 2023, and provided a corporate update. “The expansion of our NX-2127 clinical trial in non-Hodgkin's lymphomas provides an opportunity to identify clinical benefit in a significant patient population,” said Arthur T.

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated in patients with mantle cell lymphoma (MCL)

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 192.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect?

SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17th at 4:35 p.m. ET.

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 233.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Nurix Therapeutics, Inc Stock (NRIX)